4 January 2023 - In 2026, the Inflation Reduction Act will allow the Centers for Medicare and Medicaid Services to negotiate the maximum price of certain prescription drugs on behalf of Medicare beneficiaries for the first time in the history of the program. 

While the Act specifies the criteria for selecting drugs eligible for negotiations—brand-name drugs that do not have generic equivalents and that account for the greatest Medicare spending—there are no specific instructions on how these negotiations should happen.

Read Health Affairs article